Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559590 | 0.79 | CYP2D6 (0.30) | — | |
| SCHEMBL28257454 | 0.78 | CHRM3 (0.32) | — | |
| SCHEMBL1993732 | 0.78 | — | — | |
| SCHEMBL4275581 | 0.75 | CYP2D6 (0.32) | — | |
| SCHEMBL20212754 | 0.75 | ESR1 (0.36) | HSD11B1 | |
| SCHEMBL2912964 | 0.75 | KCNQ3 (0.32) | HSD11B1 | |
| SCHEMBL6134918 | 0.74 | CES2 (0.33) | — | |
| SCHEMBL29090707 | 0.73 | CYP1A2 (0.40) | — | |
| SCHEMBL15355468 | 0.73 | — | — | |
| SCHEMBL2721518 | 0.73 | MLYCD (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465601-B2 | Uses of phosphodiesterase inhibitors | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-11-11 | — | — | US | disclosed |
| US-12234233-B2 | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-02-25 | — | — | US | disclosed |
| US-20230125064-A2 | CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR,PREPARATION METHOD THEREFOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-04-20 | — | — | US | disclosed |
| CN-111471059-B | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-111658653-B | Use of phosphodiesterase inhibitors | 药捷安康(南京)科技股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11434248-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2022-09-06 | — | — | US | disclosed |
| US-20220194934-A1 | CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR,PREPARATION METHOD THEREFOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-06-23 | — | — | US | disclosed |
| US-20220160696-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-05-26 | — | — | US | disclosed |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| CN-113956252-A | PDE9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-01-21 | — | — | CN | disclosed |
| WO-2020187165-A1 | CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2020-09-24 | — | — | WO | disclosed |
| CN-111689958-A | Crystal forms of phosphodiesterase inhibitors, preparation method and uses thereof | 南京药捷安康生物科技有限公司 | 2020-09-22 | — | — | CN | disclosed |
| WO-2020182076-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | 南京药捷安康生物科技有限公司 | 2020-09-17 | — | — | WO | disclosed |
| CN-111658653-A | Use of phosphodiesterase inhibitors | 南京药捷安康生物科技有限公司 | 2020-09-15 | — | — | CN | disclosed |
| EP-3689876-A1 | PDE9 INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-08-05 | — | — | EP | disclosed |
| CN-111471059-A | PDE9 inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-20200115384-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2020-04-16 | — | — | US | disclosed |
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | HSD11B1 201/4885 |
| US-12234233-B2 | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | PDE3A, PDE5A, PDE3B | HSD11B1 48/4885 |
| US-11434248-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | HSD11B1 69/4885 |
| US-20220194934-A1 | CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR,PREPARATION METHOD THEREFOR AND USE THEREOF | PDE3A, PDE5A, PDE3B | HSD11B1 48/4885 |
| US-20200115384-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE3A, PDE9A, PDE3B | HSD11B1 69/4885 |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE9A, PDE12, PDE5A | HSD11B1 40/4885 |
| US-20230125064-A2 | CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR,PREPARATION METHOD THEREFOR AND USE THEREOF | PDE3A, PDE5A, PDE3B | HSD11B1 48/4885 |
| US-12465601-B2 | Uses of phosphodiesterase inhibitors | PDE3A, PDE3B, PDE5A | HSD11B1 32/4885 |
| US-20220160696-A1 | USES OF PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE3B, PDE5A | HSD11B1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.